Previous close | 32.48 |
Open | 31.79 |
Bid | 32.47 x 50000 |
Ask | 32.88 x 50000 |
Day's range | 31.79 - 31.79 |
52-week range | 22.35 - 34.50 |
Volume | |
Avg. volume | 72 |
Market cap | 61.845B |
Beta (5Y monthly) | 0.25 |
PE ratio (TTM) | 52.11 |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | 0.36 (1.12%) |
Ex-dividend date | 27 Sept 2024 |
1y target est | N/A |
Merck stock tumbled under its 50-day moving average Thursday after the FDA rejected its Daiichi Sankyo-partnered cancer drug.
The FDA's CRL to Merck (MRK) and its partner Daiichi Sankyo for the patritumab deruxtecan BLA is based on observations made on inspection of a third-party manufacturing facility.
AstraZeneca's (AZN) shares decline as it fails to achieve statistically significant overall survival data in a late-stage NSCLC study on Dato-DXd compared with docetaxel.